The keywords with the strongest citation burst in the past 5 years included “tumor microenvironment”, “multicenter”, “PD 1 blockade”, “checkpoint inhibitor”, “immune checkpoint inhibitor”, and “placebo”, suggesting that studies related to ICI are currently popular topics in PCa immunotherapy. This evidence concerns the gene RPL17 and neoplasm.